CSL Ltd Annual Report 2019

19 Bleeding disorders continued Mohammed and his younger brother AL Bara’a, both with severe haemophilia B, receiving WFH Humanitarian Aid Program treatment at Al Bashir hospital – Amman, Jordan. Photo courtesy of the WFH Humanitarian Aid Program CSL Behring will also participate as a “Collaborating Partner” of the World Bleeding Disorders Registry (WBDR), the only global registry collecting standardised clinical data on haemophilia patients. In addition, CSL Behring will continue to be a significant contributor to the WFH Humanitarian Aid Program’s efforts to provide consistent and predictable treatment access through product donations and financial support. All of these programs reinforce our promise to patients by empowering them through education and advocacy, raising awareness, advancing scientific knowledge and improving access to care. Influenza In 2018, Seqirus continued its support for theWorld Health Organization’s (WHO) Pandemic Influenza Preparedness (PIP) Framework with a corporate contribution. The program aims to improve the sharing of influenza viruses with pandemic potential and the equitable access to products necessary to respond to pandemic influenza (e.g., vaccines, antiviral medicines and diagnostic products). Seqirus has also agreed to donate 10% of influenza vaccine output in real time toWHO for deployment to developing countries in the event of a global pandemic emergency. Seqirus has continued to support the Partnership for Influenza Vaccine Introduction (PIVI), a key program of the Task Force for Global Health, a not-for-profit, independent, nongovernmental organisation based in the US. An innovative public/private program, PIVI works in partnership with the Centers for Disease Control and Prevention (CDC), Ministries of Health, corporate partners and others to create sustainable, routine, seasonal influenza vaccination programs in low and middle-income countries. In the past year, our financial support to PIVI has focused on the establishment of a global coalition to explore the value of a coordinated stakeholders plan for epidemic and pandemic influenza preparedness. Snakebite The first year of a three-year multi-year stakeholder partnership, to help save lives from snakebite in Papua New Guinea (PNG) was successfully completed. PNG has some of the highest rates of snakebite mortality in the world, caused mainly by taipan and death adder envenomation. The same snake species are found in Australia, where Seqirus antivenom has been in use for decades. The partnership, involving the PNG National Department of Health, the Australian High Commission, Seqirus and the Charles Campbell Toxinology Centre, at the University of Papua New Guinea, is intended to significantly improve access to antivenoms by combining a large product donation with healthcare worker training and a purpose-built cold-chain distribution and product management system. Seqirus donated 600 vials of snake and marine creature antivenoms, valued at more than A$1 million to PNG in this first year. Influenza Commitment to donate 10% of influenza vaccine output in the event of a global pandemic. 600 vials of snake and marine antivenom donated to Papua New Guinea. CSL Limited Annual Report 2019 38 Working with Our Communities